7 U.S. Stocks to Buy on Coronavirus Weakness

The coronavirus outbreak is a short-term problem, and these are stocks are long-term winners

[Editor’s note: This story has been updated to include Johnson & Johnson and CVS Health Corp. It removes Crocs Inc. and Skechers USA.]

The outbreak of China’s coronavirus is a big deal. To date, it has infected over 40,000 people across the globe, and killed at least 1,100. Even if the disease stopped spreading today — which it won’t — this outbreak will still go down as one of the most pervasive epidemics in modern world history.

And yet, markets don’t seem to care. U.S. stocks dropped big on Friday, Jan. 31, on coronavirus concerns. And that was it. Ever since, stocks have been in rally mode, with the S&P 500 cruising to fresh all-time highs in early February.

Why? Because, while the coronavirus outbreak is a big deal, it’s also a short-term deal. Outbreaks happen all the time. They never last more than a few months. They hit, they spread, they peak, they go down and within a few months, they’re gone. Their impact on the economy, while severe for a few months, is short-lived, and economic activity always rebounds sharply as soon as the virus disappears.

It also helps that: 1) the Wuhan coronavirus isn’t as deadly as other viruses with a mere 2% fatality rate (SARS, by comparison, had a 10% fatality rate), 2) it’s largely contained to China, 3) significant progress has been made on a potential treatment or cure, and 4) in response to the virus outbreak, China has injected tons of fiscal stimuli and halved tariffs on U.S. goods.

Consequently, when it comes to the coronavirus, you have a short-term problem. The best investment game-plan is to buy the short-term weakness in long-term winners, not to chase short-term strength in short-term winners.

As Clinical Professor of Finance David Kass at the University of Maryland’s Robert H. Smith School of Business wrote in an email to InvestorPlace:

“The worldwide fear of the coronavirus is likely to result in the outperformance of health stocks in the near future … [but] biotech stocks trying to develop a vaccine for this virus … have already had large stocks moves to the upside. Instead of those highly visible potential beneficiaries of the spreading of this disease, I suggest looking elsewhere within the healthcare sector.”

I already picked some Chinese stocks to buy once coronavirus fears fade. Now, I’m picking seven U.S. stocks to buy on coronavirus weakness.

Without further ado, let’s take a look at those names.

Stocks to Buy: Apple (AAPL)

Global technology giant Apple (NASDAQ:AAPL) has been hit hard from multiple angles thanks to the coronavirus outbreak in China. First, the company closed all corporate offices, stores and contact centers in mainland China until Feb. 9. Second, many of Apple’s suppliers have been ordered to reduce or altogether halt production until Feb. 10. Third, thanks to the production pause, Apple’s AirPods may have a supply shortage for the new few weeks.

None of that is great news, especially since China is a big part of the Apple growth narrative. As such, it should be no surprise that Apple stock dropped 5% Jan. 31 on coronavirus fears.

But, Apple will be just fine. This is true for a few reasons. First, the App Store will get a big boost during the outbreak (there are hundreds of millions of Chinese consumers stuck at home, desperate for ways to entertain themselves). Second, February typically isn’t a big month for iPhone sales. Third, because an iPhone is a big-ticket purchase, any lost demand during February won’t forever disappear — it will just shift into March or April. Fourth, Apple’s big iPhone launch comes in the back half of 2020. By then, the outbreak should be old news.

All in all, Apple will weather the coronavirus storm just fine, and the company is still staring at huge growth potential in the back half of the year.

Nike (NKE)

Shares of global athletic apparel giant Nike (NYSE:NKE) dropped about 8% in late January on concerns that the coronavirus outbreak could materially impact the company’s operations in China.

Those concerns were confirmed in early February, when management said in a press release that they expect the outbreak to have a “material impact” on operations in China. The company said it has shut down about half of its stores in China. Those that remain open are operating at reduced hours with lower-than-usual traffic volumes.

That’s not great news for Nike. A slowdown in this big and hyper-growth segment will have ripple effects across Nike’s entire business.

But, this negative impact will be short-lived. During the SARS epidemic, retail sales in China slowed during the outbreak, but as soon as the outbreak cleared up, retail sales trends came roaring back to life in a hurry. The same thing should happen this time around, especially since the People’s Bank of China (PBOC) has injected stimulus packages and tariffs on U.S. goods have been halved. Thus, once the outbreak ends, retail sales in China will accelerate meaningfully, and Nike’s China business will get back to firing on all cylinders.

Advanced Micro Devices (AMD)

In the last week of January, shares of red-hot chip maker Advanced Micro Devices (NASDAQ:AMD) dropped about 10% amid concerns that the coronavirus outbreak would dampen chip demand in China. To make matters worse, AMD reported mixed fourth-quarter numbers in late January that included a light first-quarter revenue guide.

But, these concerns seem overstated.

As I’ve written before, global epidemics historically tend not to have an impact on the semiconductor market. SARS didn’t hit the semiconductor market in 2002. On the contrary, global semiconductor sales actually rose during the SARS outbreak. Similarly, during the H7N9 outbreak in the 2010s, global semiconductor sales rose.

The same thing should happen this time, especially since U.S-China trade tensions are easing while central banks through Asia are rushing to inject stimulus packages and support their economies. Once this outbreak ends, corporate spending on things like semiconductor chips should roar higher. AMD’s numbers will charge even higher, since this company remains the market share leader in critical verticals of the semiconductor market.

Big picture — coronavirus weakness in AMD stock is overstated. Over the next few months, the fundamentals underlying AMD will improve, not deteriorate. As they do, AMD stock will go higher, not lower.

Johnson & Johnson (JNJ)

Professor Kass from the University of Maryland is bullish on healthcare stocks, with the rationale being that the coronavirus outbreak will create a multi-year tailwind for healthcare spending in the United States.

“… several stocks that are currently under the radar for this possible epidemic should do very well as healthcare spending in the years ahead is likely to increase substantially,” said Kass.

One of his top stock picks in the healthcare industry is Johnson & Johnson (NYSE:JNJ), and I agree that the coronavirus outbreak will create a long-term tailwind for Jonson & Johnson stock.

The thinking is pretty simple. Johnson & Johnson sells a variety of everyday healthcare products to U.S. consumers. While U.S. consumers at large weren’t directly impacted by the coronavirus, they were indirectly impacted through a elevated sense of personal health caution. This elevated sense of caution will inevitably result in consumers spending more on things like hand-wash, wipes, sanitizers, disinfectants, etc.

Johnson & Johnson sells a lot of that stuff. Consequently, demand for Johnson & Johnson products should rise over the next few years as consumers become for health-conscious. “[Johnson & Johnson] is likely to continue experiencing rapid growth in revenues and earnings in the foreseeable future,” says Professor Kass.

I couldn’t agree more. And this sustained revenue and earnings growth lays a foundation for Johnson & Johnson stock to head higher.

Intel (INTC)

The bull thesis on global semiconductor giant Intel (NASDAQ:INTC) is very similar to the bull thesis on Advanced Micro Devices.

Specifically, Intel stock dropped about 8% in late January on fears that the coronavirus outbreak in China would dampen global semiconductor demand. But, historically speaking, Chinese-originated global epidemics don’t have a meaningful impact on global semiconductor demand. On the contrary, global semiconductor sales rose in 2002-03 amid the SARS outbreak, and in the 2010s amid the H7N9 outbreak.

Meanwhile, Intel just reported a blowout fourth-quarter earnings report and delivered a robust first-quarter guide, the sum of which imply that demand in the company’s core data-centric markets is rebounding, not falling.

It will take more than a short-term epidemic in China to derail these rebounding demand trends. Plus, once the epidemic fades, these data-centric demand trends will actually accelerate higher, because of stimulus from Asian central banks as well as accelerated U.S.-China trade war deescalation.

Broadly, then, the most likely path forward for Intel stock in 2020 is higher, not lower.

Starbucks (SBUX)

Much like Nike, global coffee house operator Starbucks (NASDAQ:SBUX) has been forced to close about half of its cafes in China, with an unclear timeline as to when those stores will re-open. Also, echoing what management at Nike said, Starbucks management said that they expect the outbreak to have a “materially” negative impact on current quarter and full-year numbers.

In response to that news, Starbucks stock has shed about 10% off its mid-January highs.

But, while China remains a very important piece of the Starbucks growth narrative, the country accounts for only about 10% of Starbucks’ total revenue. So, the negative impacts won’t be that big. Further, they will be ephemeral. They won’t have any impact on the long-term growth narrative, which is centered around increasing coffee consumption, urbanization and a rising middle class in China.

If anything, tons of fiscal stimulus from the PBOC will only accelerate those longer-term trends once the outbreak passes.

As such, if Starbucks stock keeps dropping on coronavirus fears, that weakness will ultimately be nothing more than a good buying opportunity into a long-term winner.

Estee Lauder (EL)

One of the companies hit hardest by the coronavirus outbreak in China has been multinational beauty care giant Estee Lauder (NYSE:EL), who derives a whopping 17% of its sales from China.

Thanks to the broad exposure, Credit Suisse estimates that Estee Lauder could see 3% to 5% decrease in earnings per share this quarter. This profit risk is why Estee Lauder stock dropped more than 10% in the wake of the coronavirus outbreak.

But, Estee Lauder just reported fourth-quarter numbers. They were quite good, beating on both the top and bottom lines. And, while management said that retail store closures, reduced retail hours, lower store traffic volumes and travel restrictions will weigh on near-term operating results, management also sounded confident in their ability to weather the storm and mitigate adverse impacts.

Specifically, instead of running away from China, Estee Lauder is doubling down on China. It is  going to up research and development spending. It is going to build a new innovation center, launch new fragrance products this year and continue to build-out the online channel.

Management’s confident tone breathed life back into bulls. Estee Lauder stock rallied after the print. And, it appears that so long as the coronavirus outbreak doesn’t get worse from here, this stock is on course to rebound over the next few months.

CVS Health (CVS)

Another healthcare stock which Professor Kass is bullish on in the near-term is CVS Health (NYSE:CVS):

“As the nation’s foremost integrated health-care services provider, its revenues and profits are projected to grow at a rapid rate in the years ahead.”

I agree with Professor Kass. CVS is positioned for big revenue and profit growth over the next few years, and big gains in CVS stock will follow suit.

The bull thesis here really breaks down into two parts. First, CVS has figured out how to differentiate itself in the pharmacy retail game with its new HealthHUBs, which are essentially CVS stores that include personalized healthcare stations. These HealthHUBs are turning CVS stores into one-stop-shops for all things pharmacy retail. Consumers are resonating with this value prop. Largely thanks to further expansion of HealthHUBs, CVS just reported yet another double beat earnings report. Continued expansion of HealthHUBs will lead to more double beat reports in the years ahead.

Second, heightened U.S. consumer anxiety regarding the coronavirus outbreak — which has run concurrent to a really bad flu season in America — will lead to increased consumer spend on everyday healthcare products. CVS sells all of those products. Consequently, as consumers up their spend on everyday healthcare products over the next few quarters, traffic and revenue trends at CVS should pick up.

As of this writing, Luke Lango was long AAPL.